Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS
Status:
Completed
Trial end date:
2018-12-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the effects of three-month course of treatment
modalities (Cyproterone compound-Spironolactone, Metformin and Pioglitazone) in patients with
polycystic ovary syndrome (PCOS) on markers of inflammation [serum complement, homocysteine
and high sensitive C-reactive protein (hs-CRP)] levels.